Last reviewed · How we verify
NCT07173192
The Effect of an Individual Empowerment Program Provided to Relatives of Schizophrenia Patients
NA trial testing Individual empowerment program in Schizophrenia in 66 participants. Enrolling by invitation.
30 November 2025
Quick facts
| Lead sponsor | Istanbul Arel University |
|---|---|
| Phase | NA |
| Status | ENROLLING BY INVITATION |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 66 |
| Start date | 15 May 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 15 February 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Individual empowerment program
Conditions studied
- Schizophrenia — all drugs for Schizophrenia →
Sponsor
Istanbul Arel University
Who can join
Adults 18 to 65, any sex, with Schizophrenia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Psychoeducation provided to family members caring for individuals with schizophrenia. Has been found to positively impact caregivers' psychological well-being and the effective management of schizophrenia patients.However, further experimental studies are recommended in this area, along with support for caregivers' psychological well-being. Primary caregivers, which includes both psychoeducation and applications aimed at developing coping skills, on the care burden, psychological well-being,and self-efficacy. Considering the gaps in the literature, the aim of this study is to evaluate the effect of an individual empowerment program applied to primary caregivers of patients diagnosed with schizophrenia on the burden of care, psychological well-being, and self-efficacy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07173192
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Schizophrenia
Currently open trials in the same condition.
- NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
- NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
- NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
- NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
- NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting
Other Istanbul Arel University trials
Trials by the same sponsor.
- NCT07518082 — Effect of Virtual Reality-Based Handwashing Education on Knowledge, Skills, and Attitudes in Preschool Children · NA · not yet recruiting
- NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
- NCT07478406 — Relatıonshıp Between Pelvıc Floor and Venous Insuffıcıency · NA · enrolling by invitation
- NCT07432464 — The Effect of Nomophobia Levels on Anxiety and Academic Self-Efficacy in Students With Text Neck · not yet recruiting
- NCT07402187 — "Productivity Training and Job Stress Among Nurses" · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07173192 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul Arel University
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07173192.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing